{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:33:45Z","timestamp":1789706025855,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Shandong Province Medical and Health Technology Development Program"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","amjmedsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.amjms.2018.01.017","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T08:48:15Z","timestamp":1517561295000},"page":"418-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy"],"prefix":"10.1016","volume":"355","author":[{"given":"Yingying","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2018.01.017_bib1","first-page":"447","article-title":"Guidelines for prevention and treatment of type 2 diabetes in China","volume":"7","year":"2014","journal-title":"Chin J Diabetes Mellitus (Article in Chinese)"},{"key":"10.1016\/j.amjms.2018.01.017_bib2","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2018.01.017_bib3","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjms.2018.01.017_bib4","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s10157-015-1106-2","article-title":"Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial","volume":"19","author":"Kato","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.amjms.2018.01.017_bib5","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2018.01.017_bib6","unstructured":"Writing Group of 2010 Chinese Guidelines for the Management of Hypertension. 2010 Chinese guidelines for the management of hypertension. Chin J Cardiol (Article in Chinese) 2011; 39: 579-616."},{"key":"10.1016\/j.amjms.2018.01.017_bib7","first-page":"371","article-title":"Expert consensus of HbA1c control target for Chinese adult with type 2 diabetes","volume":"27","year":"2011","journal-title":"Chin J Endocrinol Metab (Article in Chinese)"},{"key":"10.1016\/j.amjms.2018.01.017_bib8","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjms.2018.01.017_bib9","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1185\/03007995.2015.1094044","article-title":"Can levothyroxine treatment reduce urinary albumin excretion rate in patients with early type 2 diabetic nephropathy and subclinical hypothyroidism? A randomized double-blind and placebo-controlled study","volume":"31","author":"Liu","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjms.2018.01.017_bib10","first-page":"792","article-title":"Expert consensus on prevention and treatment of diabetic nephropathy (2014)","volume":"6","year":"2014","journal-title":"Chin J Diabetes Mellitus (Article in Chinese)"},{"key":"10.1016\/j.amjms.2018.01.017_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejim.2013.11.007","article-title":"Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review","volume":"25","author":"Mavrakanas","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.amjms.2018.01.017_bib12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2710.2005.00694.x","article-title":"Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil","volume":"30","author":"Saito","year":"2005","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.amjms.2018.01.017_bib13","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/ndt\/gft281","article-title":"Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin 2 receptor blocker in patients with diabetic nephropathy: a randomized clinical trial","volume":"28","author":"Esteghamati","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjms.2018.01.017_bib14","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meirackera","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjms.2018.01.017_bib15","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjms.2018.01.017_bib16","article-title":"Spironolactone for hypertension","volume":"8","author":"Batterink","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amjms.2018.01.017_bib17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/10641963.2010.531844","article-title":"Low-dose and very low-dose spironolactone in combination therapy for essential hypertension: evaluation by self-measurement of blood pressure at home","volume":"33","author":"Hanazawa","year":"2011","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.amjms.2018.01.017_bib18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/dmrr.2768","article-title":"Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus\u2014a 4.6-year cohort study","volume":"32","author":"Chang","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.amjms.2018.01.017_bib19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/cen.12673","article-title":"Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study","volume":"83","author":"Liu","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.amjms.2018.01.017_bib20","first-page":"913","article-title":"China expert consensus on treatment of hyperuricemia and gout","volume":"29","year":"2013","journal-title":"Chin J Endocrinol Metab (Article in Chinese)"},{"key":"10.1016\/j.amjms.2018.01.017_bib21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1475-2840-12-159","article-title":"Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study","volume":"12","author":"Nishida","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjms.2018.01.017_bib22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/2040622315596119","article-title":"The effect of angiotensin II receptor blockers on hyperuricemia","volume":"6","author":"Wolff","year":"2015","journal-title":"Adv Chronic Dis"},{"key":"10.1016\/j.amjms.2018.01.017_bib23","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962918300521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962918300521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:24:43Z","timestamp":1617236683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962918300521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0002962918300521"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2018.01.017","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2018.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Southern Society for Clinical Investigation. Published by All rights reserved.","name":"copyright","label":"Copyright"}]}}